Sleep Trial to Prevent Alzheimer's Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age65+
SponsorUniversity of Minnesota
About this trial
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
Eligibility criteria
Qualifiers
Male or female.
Any race or ethnicity.
Participants must be age ≥65 years and able to sign informed consent.
Global Clinical Dementia Rating (CDR) 0.
Disqualifiers
History of reported symptoms suggestive of restless legs syndrome, narcolepsy or other central disorder of hypersomnolence, or parasomnia
STOP-Bang score >6 for participants without PAP
Untreated OSA with AHI ≥15 on home sleep test
Treated sleep apnea with PAP non-compliance
Trial design
Treatments tested in this trial
- Suvorexant 20 mg
- Placebo
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov